Ranjan Dutta

Ranjan Dutta

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 August 2020 in Science
Verified
Journal Article
Closed access
FHFiachra Humphries
Fiachra Humphries
LSLiraz Shmuel-Galia
Liraz Shmuel-Galia
NKNatalia Ketelut-Carneiro
Natalia Ketelut-Carneiro
SLSheng Li
Sheng Li
BWBingwei Wang
Bingwei Wang
KFKate Fitzgerald
Kate Fitzgerald
Fumarate targets pyroptosis: A form of inflammatory cell death called pyroptosis depends on the caspase-mediated cleavage of gasdermin D (GSDMD), the fragments of which assemble into permeability pores that then kill the cell. The mechanisms regulating this important cellular process are not yet fully understood. Humphries et al. now report that the tricarboxylic acid cycle intermediate fumarate can act as an inhibitor of pyroptosis (see the Perspective by Pickering and Bryant). Both endogenous fumarate and exogenously delivered dimethyl fumarate (DMF) convert the cysteines in GSDMD to S-(2-succinyl)-cysteines (a process called succination) to prevent its interaction with caspases and subsequent processing and activation. Administration of DMF to mice alleviated inflammation in models of multiple sclerosis and familial Mediterranean fever. These findings may explain the efficacy of DMF as a treatment for multiple sclerosis and other inflammatory diseases and offer insights into future anti-inflammatory drug design. Science , this issue p. 1633 ; see also p. 1564

29 August 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
LKLeslie Kirby
Leslie Kirby
JJJing Jin
Jing Jin
JCJaime Gonzalez Cardona
Jaime Gonzalez Cardona
MSMatthew D. Smith
Matthew D. Smith
KMKyle A. Martin
Kyle A. Martin
PCPeter A Calabresi
Peter A Calabresi
Oligodendrocyte precursor cells (OPCs) are abundant in the adult central nervous system, and have the capacity to regenerate oligodendrocytes and myelin. However, in inflammatory diseases such as multiple sclerosis (MS) remyelination is often incomplete. To investigate how neuroinflammation influences OPCs, we perform in vivo fate-tracing in an inflammatory demyelinating mouse model. Here we report that OPC differentiation is inhibited by both effector T cells and IFNγ overexpression by astrocytes. IFNγ also reduces the absolute number of OPCs and alters remaining OPCs by inducing the immunoproteasome and MHC class I. In vitro, OPCs exposed to IFNγ cross-present antigen to cytotoxic CD8 T cells, resulting in OPC death. In human demyelinated MS brain lesions, but not normal appearing white matter, oligodendroglia exhibit enhanced expression of the immunoproteasome subunit PSMB8. Therefore, OPCs may be co-opted by the immune system in MS to perpetuate the autoimmune response, suggesting that inhibiting immune activation of OPCs may facilitate remyelination.

1 July 2020 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
PBPavan Bhargava
Pavan Bhargava
MSMatthew D. Smith
Matthew D. Smith
LMLeah Mische
Leah Mische
EHEmily Harrington
Emily Harrington
KFKathryn Fitzgerald
Kathryn Fitzgerald
PCPeter A Calabresi
Peter A Calabresi
Multiple sclerosis (MS) is an inflammatory demyelinating disorder of the CNS. Bile acids are cholesterol metabolites that can signal through receptors on cells throughout the body, including in the CNS and the immune system. Whether bile acid metabolism is abnormal in MS is unknown. Using global and targeted metabolomic profiling, we identified lower levels of circulating bile acid metabolites in multiple cohorts of adult and pediatric patients with MS compared with controls. In white matter lesions from MS brain tissue, we noted the presence of bile acid receptors on immune and glial cells. To mechanistically examine the implications of lower levels of bile acids in MS, we studied the in vitro effects of an endogenous bile acid, tauroursodeoxycholic acid (TUDCA), on astrocyte and microglial polarization. TUDCA prevented neurotoxic (A1) polarization of astrocytes and proinflammatory polarization of microglia in a dose-dependent manner. TUDCA supplementation in experimental autoimmune encephalomyelitis reduced the severity of disease through its effects on G protein–coupled bile acid receptor 1 (GPBAR1). We demonstrate that bile acid metabolism was altered in MS and that bile acid supplementation prevented polarization of astrocytes and microglia to neurotoxic phenotypes and ameliorated neuropathology in an animal model of MS. These findings identify dysregulated bile acid metabolism as a potential therapeutic target in MS.

1 June 2014 in Current Opinion in Neurology
Verified
Journal Article
Closed access
RDRanjan Dutta
Ranjan Dutta
BTBruce D. Trapp
Bruce D. Trapp
Purpose of review The predominant clinical disease course of multiple sclerosis starts with reversible episodes of neurological disability, which transforms into progressive neurological decline. This review provides insight into the pathological differences during relapsing and progressive phases of multiple sclerosis. Recent findings The clinical course of multiple sclerosis is variable, and the disease can be classified into relapsing and progressive phases. Pathological studies have been successful in distinguishing between these two forms of the disease and correlate with the clinical findings in terms of cellular responses, the inflammatory environment, and the location of lesions. Summary Available therapies for multiple sclerosis patients, while effective during the relapsing phase, have little benefit for progressive multiple sclerosis patients. Development of therapies to benefit progressive multiple sclerosis patients will require a better understanding of the pathogenesis of progressive multiple sclerosis. This review discusses and compares the pathological findings in relapsing and progressive multiple sclerosis patients.

11 February 2013 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
RDRanjan Dutta
Ranjan Dutta
ACAnthony M. Chomyk
Anthony M. Chomyk
ACAnsi Chang
Ansi Chang
MRMichael V. Ribaudo
Michael V. Ribaudo
SDSadie A. Deckard
Sadie A. Deckard
BTBruce D. Trapp
Bruce D. Trapp

18 June 2019 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
DKDavid Kremer
David Kremer
JGJoel Gruchot
Joel Gruchot
VWVivien Weyers
Vivien Weyers
LOLisa Oldemeier
Lisa Oldemeier
PGPeter Göttle
Peter Göttle
Patrick KueryPatrick Kuery
Patrick Kuery
Significance: There is a broad repertoire of immunomodulatory drugs that effectively treat the inflammatory aspects of relapsing multiple sclerosis (MS). However, axonal degeneration, which occurs mainly in progressive MS, is still not understood and cannot be treated pharmaceutically. As it is the major factor contributing to clinical disability in MS, it represents an unmet clinical need. A recently completed phase IIb study has demonstrated that anti-pathogenic human endogenous retrovirus type W (pHERV-W) envelope protein (ENV) treatment results in a significant decrease of neurodegenerative brain atrophy in treated MS patients. For these results, the work presented here offers an explanation by demonstrating that, via myeloid cells, pHERV-W ENV directly harms axons.